Stuttgart
24.01.25
08:15 Uhr
5,950 Euro
-0,050
-0,83 %
-0,83 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Nxera Pharma Webinar Presentation for FY2024 Financial Results | 1 | GlobeNewswire (USA) | ||
| 14.01. | Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio | 11 | GlobeNewswire (USA) | ||
| 19.12.24 | Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia | 14 | GlobeNewswire (USA) | ||
| 05.12.24 | Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea | 93 | GlobeNewswire (Europe) | Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected... ► Artikel lesen | |
| 13.11.24 | Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist | 238 | GlobeNewswire (Europe) | Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 - Nxera Pharma Co., Ltd. ("Nxera"... ► Artikel lesen | |
| 06.11.24 | Nxera Pharma and Antiverse to design antibodies targeting GPCRs | 4 | Pharmaceutical Technology | ||
| 05.11.24 | Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI | 8 | GlobeNewswire (USA) | ||
| NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.11.24 | Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024 | 160 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 1 November 2024 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) - formerly known as Sosei Group or Sosei Heptares - provides an update on operational... ► Artikel lesen | |
| 23.10.24 | Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 | 12 | GlobeNewswire (USA) | ||
| 18.10.24 | Nxera Pharma to Host R&D Day 2024 | 1 | GlobeNewswire (USA) | ||
| 01.10.24 | Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan | 278 | GlobeNewswire (Europe) | QUVIVIQ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024... ► Artikel lesen | |
| 01.10.24 | Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan | 152 | GlobeNewswire (Europe) | Dr. Sugita - formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan - brings nearly 20 years' experience in R&D and commercial roles working within the Japanese businesses of global... ► Artikel lesen | |
| 24.09.24 | Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia | 342 | GlobeNewswire (Europe) | The approval of QUVIVIQ, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpointsPlans... ► Artikel lesen | |
| 13.09.24 | Nxera and Cancer Research UK to present promising cancer drug trial at ESMO | 2 | PharmaTimes | ||
| 13.09.24 | Nxera Pharma: Nxera's Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO | 2 | GlobeNewswire (USA) | ||
| 11.09.24 | Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers | 231 | GlobeNewswire (Europe) | ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency and had a favorable safety and tolerability profile with no observations of frequently reported... ► Artikel lesen | |
| 02.09.24 | Nxera wins $35m after Phase II schizophrenia trial success | 1 | Pharmaceutical Technology | ||
| 02.09.24 | Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 | 320 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 September 2024 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) - formerly known as Sosei Group or Sosei Heptares - announces that it will receive a... ► Artikel lesen | |
| 28.08.24 | Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 | 433 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily... ► Artikel lesen | |
| 09.08.24 | Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024 | 188 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 9 August 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second... ► Artikel lesen |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,800 | -2,25 % | Pfizer Aktie: Was Analysten zu berichten haben | Die US-amerikanische Pharmafirma Pfizer steht aktuell vor wichtigen strategischen Veränderungen. Der Konzern plant bedeutende Verkaufsaktivitäten, während die Aktie am letzten Handelstag bei 26,31 USD... ► Artikel lesen | |
| NOVARTIS | 94,84 | -0,70 % | JEFFERIES stuft NOVARTIS AG auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Novartis von 105 auf 100 Franken gesenkt und die Einstufung auf "Hold" belassen. Bei den Schweizern sieht sich Analyst Peter... ► Artikel lesen | |
| GILEAD SCIENCES | 88,90 | -0,34 % | Bleibt Big Tech Ertragsbringer? Ausblick, News und Hintergründe - Calling USA | ||
| SANOFI | 99,98 | +0,07 % | Sanofi SA-Aktie mit leichten Kursgewinnen (99,89 €) | An der Börse liegt die Aktie von Sanofi SA aktuell im Plus. Das Papier notiert zur Stunde bei 99,89 Euro. Freuen können sich gegenwärtig die Aktionäre von Sanofi SA: Die Aktie weist derzeit einen Wertanstieg... ► Artikel lesen | |
| ABBVIE | 162,26 | -0,95 % | AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology | WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets... ► Artikel lesen | |
| ROCHE | 289,15 | -0,43 % | JPMORGAN stuft ROCHE HOLDINGS AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche vor Geschäftszahlen des Pharmakonzerns mit einem Kursziel von 230 Franken auf "Underweight" belassen. Alles in allem dürften... ► Artikel lesen | |
| ABBOTT LABORATORIES | 118,94 | +0,56 % | Bericht der Quartalszahlen: Dividenden-Aristokrat Abbott bleibt leicht unter den Erwartungen | © Foto: adobe.stock.comDer US-Medizingerätehersteller Abbott zeigt sich im abgelaufenen Quartal leicht hinter den Erwartungen der Analysten, kann jedoch mit seiner Prognose für 2025 glänzen.Während... ► Artikel lesen | |
| INCYTE | 69,42 | -0,29 % | Notable Insider Move: PABLO CAGNONI Takes Part In Options Exercise At Incyte, Resulting In $0 | ||
| EDWARDS LIFESCIENCES | 65,58 | -0,88 % | Edwards Lifesciences Projects 2025 Constant Currency Sales Growth Of 8% - 10% | WASHINGTON (dpa-AFX) - Edwards Lifesciences (EW) reaffirmed original 2024 total company constant currency sales growth guidance of 8% to 10%. The company is projecting 2025 constant currency... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,140 | +6,06 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
| HALEON | 4,472 | -0,78 % | Pfizer Sells GBP 2.50 Bln Of Shares In Haleon | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare company, at 357 pence per share... ► Artikel lesen | |
| BIONANO GENOMICS | 0,121 | -8,38 % | Bionano Genomics: Bionano Announces Effective Date of Reverse Stock Split | SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stock... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,387 | +16,99 % | Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 13.2% Higher - Here's Why | ||
| ALNYLAM PHARMACEUTICALS | 264,90 | +0,08 % | Alnylam Pharma Anticipates Achieving Non-GAAP Profitability In 2025 | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) anticipates delivering non-GAAP operating income profitability in 2025.Alnylam announced full year 2025 combined net product revenue... ► Artikel lesen | |
| GRIFOLS | 8,732 | +1,11 % | Grifols falls as Spanish regulator mulls sanctions against directors |
NXERA PHARMA CO LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 5,950 Euro und damit -0,83 % im Minus. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NXERA PHARMA CO LTD finden Sie auf Wallstreet Online.
